Menu

Jury Finds Monsanto’s Roundup Responsible for Man’s Cancer

A San Francisco court levels $289 Million in damages against the pesticide maker.

Aug 13, 2018
Sukanya Charuchandra

ABOVE: ©ISTOCK, AMYKERK

ASuperior Court jury in California on August 10 granted Dewayne Johnson $289 million in damages from Monsanto for its Roundup weed killer having caused his cancer. This is the first of more than 5,000 lawsuits Monsanto faces for its glyphosate-based weed killers. Johnson's case, filed in 2016, was fast-tracked because of the speed at which his non-Hodgkin lymphoma was progressing, according to Reuters

The San Francisco jury took three days to deliver its verdict. Jury members agreed the company should have labeled Roundup as hazardous. One of Johnson’s lawyers, Brent Wisner, says in a statement that Monsanto knew “glyphosate and specifically Roundup could cause cancer,” according to company records. 

See “How Toxic Is the World’s Most Popular Herbicide Roundup?” 

After the trial, Scott Partridge, Monsanto’s vice president for global strategy, said the documents had been “taken completely out of context,” according to The Guardian. He added that the trial doesn't alter “the four-plus decades of safe use and science behind the product.” The company will be appealing the verdict. 

The herbicide is available in 130 countries and can be used on more than 100 crops. Further, glyphosate has been labeled as “probably carcinogenic to humans” since 2015 by the World Health Organization’s cancer arm. Partridge proclaimed the organization, whose results were central to the trial, as “having been corrupted,” according to The Guardian

Johnson used two Monsanto products, Roundup and Ranger Pro, in his job as a pest control manager for a San Francisco Bay Area school district. He applied large volumes of the herbicide to school grounds, sometimes winding up covered in the product due to heavy winds. According to the US Environmental Protection Agency, glyphosate is safe if used according to its label. 

A lawyer for Monsanto, George Lombardi, says Johnson’s cancer type takes several years to appear and must have started before he was employed by the county, according to the Associated Press

According to the Associated Press, Johnson told reporters at a press conference following the judgment, “This case is way bigger than me. I hope it gets the attention that it needs.”

Monsanto was acquired by the German company Bayer in a $66 billion dollar deal completed in June this year. In response to the verdict, Bayer’s stocks have fallen by 12 percent today (August 13) in Frankfurt, reports Bloomberg. Bayer may have to shell out a hefty amount in damages for its recent purchase when other cases against Monsanto go to trial. Between 2 percent to 3 percent of its earnings are credited to Roundup, according to Bloomberg. Additionally, Monsanto earns more money from its genetically engineered, Roundup-resistant seeds than from the weed killer alone. 

See “Monsanto and Bayer Announce Approval of Massive Merger

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.